JPWO2020223762A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020223762A5 JPWO2020223762A5 JP2021566041A JP2021566041A JPWO2020223762A5 JP WO2020223762 A5 JPWO2020223762 A5 JP WO2020223762A5 JP 2021566041 A JP2021566041 A JP 2021566041A JP 2021566041 A JP2021566041 A JP 2021566041A JP WO2020223762 A5 JPWO2020223762 A5 JP WO2020223762A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- cd49d
- dosing
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019901540A AU2019901540A0 (en) | 2019-05-06 | Therapeutic uses and methods | |
| AU2019901540 | 2019-05-06 | ||
| PCT/AU2020/050445 WO2020223762A1 (en) | 2019-05-06 | 2020-05-06 | Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532098A JP2022532098A (ja) | 2022-07-13 |
| JPWO2020223762A5 true JPWO2020223762A5 (enExample) | 2023-05-16 |
Family
ID=73050454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566041A Ceased JP2022532098A (ja) | 2019-05-06 | 2020-05-06 | ＣＤ４９ｄに対する阻害オリゴヌクレオチドを使用して筋ジストロフィーを治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220296631A1 (enExample) |
| EP (1) | EP3965778A4 (enExample) |
| JP (1) | JP2022532098A (enExample) |
| KR (1) | KR20220061915A (enExample) |
| CN (1) | CN114555095A (enExample) |
| AU (1) | AU2020269078A1 (enExample) |
| BR (1) | BR112021022208A2 (enExample) |
| CA (1) | CA3138945A1 (enExample) |
| WO (1) | WO2020223762A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100014333A1 (it) * | 2021-06-01 | 2022-12-01 | Materias S R L | Nuovo impiego terapeutico di inibitori della iodiotironina deiodinasi di tipo 2 (D2) |
| WO2024159266A1 (en) * | 2023-02-01 | 2024-08-08 | Antisense Therapeutics Ltd | Combination compositions and methods for treatment of muscular dystrophy |
| CN119113214B (zh) * | 2024-11-14 | 2025-02-11 | 四川大学 | 一种肌肉修复材料及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010008474A2 (en) * | 2008-06-23 | 2010-01-21 | Teva Pharmaceutical Industries, Ltd. | Methods for treating multiple sclerosis using antisense oligonucleotides |
| CA2761248C (en) * | 2009-05-08 | 2023-03-14 | Joseph Collard | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
| EP2467159A1 (en) * | 2009-08-20 | 2012-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| WO2017062835A2 (en) * | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| CA3067193A1 (en) * | 2017-06-16 | 2018-12-20 | Antisense Therapeutics Ltd | Methods for treating multiple sclerosis using antisense oligonucleotides |
| EP3787639A4 (en) * | 2018-05-04 | 2022-02-23 | Antisense Therapeutics Ltd | THERAPEUTIC USES AND PROCESSES |
-
2020
- 2020-05-06 BR BR112021022208A patent/BR112021022208A2/pt unknown
- 2020-05-06 WO PCT/AU2020/050445 patent/WO2020223762A1/en not_active Ceased
- 2020-05-06 AU AU2020269078A patent/AU2020269078A1/en active Pending
- 2020-05-06 KR KR1020217039906A patent/KR20220061915A/ko active Pending
- 2020-05-06 EP EP20801736.8A patent/EP3965778A4/en not_active Withdrawn
- 2020-05-06 CN CN202080049373.1A patent/CN114555095A/zh active Pending
- 2020-05-06 JP JP2021566041A patent/JP2022532098A/ja not_active Ceased
- 2020-05-06 US US17/609,334 patent/US20220296631A1/en not_active Abandoned
- 2020-05-06 CA CA3138945A patent/CA3138945A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009154777A4 (en) | Process for preparing and drying solid rasagiline base | |
| EP3087988A2 (en) | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto | |
| EP2442832B1 (en) | Compositions and methods for treatment of multiple sclerosis | |
| KR20250020476A (ko) | Sars-cov-2를 포함한 바이러스성 감염을 치료하는 방법 | |
| TW201446791A (zh) | 用於調節mir-122之微小rna化合物及方法 | |
| KR20170029577A (ko) | B형 간염 및 d형 간염 바이러스 감염의 치료 방법 | |
| JPWO2020061177A5 (enExample) | ||
| JP2013526519A (ja) | アンチセンスオリゴヌクレオチドを含む医薬組成物およびそれを使用する方法 | |
| WO2020259706A1 (zh) | 氨来占诺用于制备抗肝炎病毒药物的用途 | |
| ES2392449T3 (es) | Modulación antisentido de la expresión de la integrina alfa-4 | |
| RU2006124557A (ru) | Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний | |
| JP2011525531A5 (enExample) | ||
| AU2022341090B2 (en) | Treatment of neurological disorders | |
| JPWO2020223762A5 (enExample) | ||
| WO2010008474A4 (en) | Methods for treating multiple sclerosis using antisense oligonucleotides | |
| CN116568309B (zh) | 一种用于预防或治疗慢性乙型肝炎的药物组合制剂及其用途以及组合制剂试剂盒 | |
| US20240252561A1 (en) | Therapeutic pharmaceutical composition for bone and soft tissue tumors | |
| JP2024506041A (ja) | 潰瘍性大腸炎を予防、処置、または改善するためのアミセリモド | |
| EP4514968A1 (en) | Syf2 antisense oligonucleotides | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| AU2019276955A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| US20250186615A1 (en) | Induction of IL-15/IL-15RA Expression in Immune Cells | |
| TW201932114A (zh) | 化合物用於炎症介導的視神經病變的治療 | |
| HK40065449A (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
| JP6950958B2 (ja) | 核酸を含む経腸投与用組成物 |